Shares of Zimmer Biomet (NYSE:ZBH) have been assigned an average rating of “Buy” from the twenty-seven analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $139.00.
Several analysts recently commented on ZBH shares. Morgan Stanley lifted their price objective on Zimmer Biomet from $140.00 to $150.00 in a report on Monday, January 29th. BMO Capital Markets reaffirmed a “buy” rating and issued a $144.00 price objective on shares of Zimmer Biomet in a report on Tuesday, January 30th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Tuesday, January 30th. SunTrust Banks lifted their price objective on Zimmer Biomet to $142.00 and gave the stock a “buy” rating in a report on Monday, January 29th. Finally, ValuEngine raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Thursday, January 11th.
Shares of ZBH stock traded down $0.42 during mid-day trading on Friday, hitting $110.32. The company’s stock had a trading volume of 1,530,599 shares, compared to its average volume of 1,287,208. Zimmer Biomet has a 52-week low of $104.28 and a 52-week high of $133.49. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.50 and a quick ratio of 0.81. The stock has a market capitalization of $22,362.41, a P/E ratio of 13.76, a P/E/G ratio of 1.92 and a beta of 1.17.
Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.10. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The firm had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same quarter in the previous year, the business earned $2.14 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. analysts anticipate that Zimmer Biomet will post 7.8 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date is Wednesday, March 28th. Zimmer Biomet’s dividend payout ratio is presently 11.96%.
In other Zimmer Biomet news, insider Bryan C. Hanson acquired 25,077 shares of the company’s stock in a transaction dated Tuesday, February 20th. The stock was purchased at an average price of $119.68 per share, with a total value of $3,001,215.36. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Chad F. Phipps sold 20,826 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $115.95, for a total value of $2,414,774.70. The disclosure for this sale can be found here. Insiders own 0.71% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cerebellum GP LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth about $133,000. We Are One Seven LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth about $137,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Zimmer Biomet in the third quarter worth about $140,000. Chesley Taft & Associates LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth about $202,000. Finally, Harbor Advisory Corp MA purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth about $204,000. 86.34% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This news story was first posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://macondaily.com/2018/04/20/analysts-set-zimmer-biomet-zbh-price-target-at-139-00.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.